Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1 alpha antibody, in a phase III randomized study of advanced colorectal cancer

Kurzrock, R; Hickish, T; Wyrwicz, L; Saunders, M; Wu, Q; Stecher, M; Mohanty, P; Dinarello, CA; Simard, J

Kurzrock, R (reprint author), Univ Calif San Diego, Dept Med, Ctr Personalized Canc Therapy, Div Hematol Oncol,Moores Canc Ctr, San Diego, CA 92103 USA.

ONCOIMMUNOLOGY, 2019; 8 (3):

Abstract

Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1 alpha), an inflammation-mediating alarmin. IL-1 receptor antagonis......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索